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Abstract
Introduction Chronic pelvic pain (persisting pain in hips,
groins or lower back) is poorly described in studies of
cervical cancer survivors (CCSs). The aims of this study
were to describe chronic pelvic pain and associated
variables in CCSs surveyed >5 years post-radiotherapy,
and to compare the presence of pain in hips and lower back
in CCSs with findings in the general female population.
Methods Ninety-one CCSs treated with radiotherapy be-
tween 1994 and 1999 were in 2005 included in a cross-
sectional questionnaire-based study. They were asked about
demographic variables, clinical symptoms, mental distress,
and quality of life (QOL). Normative data (NORM) were
collected from a population-study of Norwegian females.
Results Pain in lower back and hips was significantly more
prevalent (p<.001) in CCSs compared to NORMs. 35/92
(38%) of the CCSs had chronic pelvic pain. These women
had significantly lower QOL, higher levels of anxiety and
depression and more bladder and intestinal problems than
those without chronic pelvic pain. In a multivariable
regression model, use of analgesics and intestinal and
bladder problems were significantly associated with chronic
pelvic pain in the CCSs.
Conclusions CCSs have a higher prevalence of pain in
lower back and hips than women in the general population,
which might be due to late effects of radiation. 35/92 (38%)
of the CCSs suffer from chronic pelvic pain, shown to be
associated with high overall mental and somatic morbidity.
Implications for Cancer Survivors Evaluation and manage-
ment of pelvic pain is important in follow-up of CCSs
treated with radiotherapy.
Keywords Pelvic pain.Cervical cancer.
Radiation therapy.Long-term survivors
Introduction
Chronic pain is a frequent complication of cancer and its
treatment, and is often underreported and poorly de-
scribed [1]. Few studies have investigated chronic pelvic
pain (here defined as pain that persists longer than the
time of natural healing located in hips, groins, lower back,
radiating pain, pain in rest or activity and/or pain
influencing daily activities) in long-term cervical cancer
survivors (CCSs) after radiotherapy. Studies on chronic
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fractures [2–4], chronic radiation enteritis, proctitis, and
cystitis usually reported by physicians [5–8]. Other painful
complications of pelvic radiation are lumbosacral plex-
opathies, chronic radiation myelopathy, lymphedema pain,
burning perineum syndrome, and osteoradionecrosis [9].
Rarely, patients suffer from chronic pelvic pain without
obvious pathology [10]. However, this diagnosis should
only be considered if the patient’s symptoms are not due
to a gynaecological cause. In clinical practice, it is
important to identify patients who suffer from treatment-
related pain, and a case finding instrument could be useful
for this purpose. However, such instruments are not
available at present, and in the majority of studies on
self-reported morbidity, pain is just rated as a single item
on a symptom-list, usually referring to back pain.
Pain has been shown to be associated with anxiety,
depression, and reduced quality of life (QOL) in cancer
survivors of various diagnoses, as well as in palliative
cancer patients [5, 11–15]. There is, however, limited
knowledge regarding such associations in CCSs after
radiotherapy.
Self-reported pain in the hips and the lower back is
common in the general female population. Some studies
show similar or even lower prevalence of such pain in
CCSs compared to healthy controls [16–19]. However,
these studies are based on small patient samples [17, 18],
often lack a clear definition of pain [16], or have included
patients with a mixture of gynaecological diagnoses and
treatment modalities [19].
On this background, the first aim of this study was to
describe chronic pelvic pain in CCSs and to explore the
differences between CCSs with and without chronic pelvic
pain regarding somatic morbidity in the pelvic organs, as
well as anxiety, depression, and QOL. Secondly, we wanted
to assess the strength of the associations between relevant
independent variables and chronic pelvic pain in CCSs
adjusted for possible confounders. Thirdly, we aimed to
investigate the prevalence of pain in hips and lower back in
CCSs after radiotherapy compared to the prevalence in the
general female population.
Patients and methods
Patients and treatment
From 1994 to 1999, almost all patients with cervical cancer
stage Ib2—IVa referred to The Radium Hospital and treated
with a curative intent were included in a prospective Nordic
Cervical Cancer Study (NOCECA). The patients in
NOCECA received external beam radiotherapy (EBRT) to
the pelvis and intra-cavitary radiotherapy (ICRT), as
described previously [6]. Briefly, for patients with tumours
≤8 cm (mostly stage Ib2 and IIb) the treatment consisted of
50–45 Gy in 25 fractions through anterior-posterior/
posterior-anterior (AP-PA) pelvic fields (Type 1) with a
treatment time of 6 weeks. In patients with tumours >8 cm
(mostly stage IIIb) the dose could optionally be raised to
60 Gy with an additional 10 Gy in five fractions with lateral
fields, extending the treatment time to 7 weeks (Type 2).
Extended radiation fields were given to patients with
enlarged para-aortic lymph nodes on MRI and proven
metastasis by image-guided biopsy (50.4 Gy/28). The dose
contribution to the bony structures of the pelvis was mainly
from the EBRT and varied according to the individual
position of the external fields. For the bony structures
encompassed by the AP-PA-fields, the dose varied from
45 Gy to 50 Gy for Type 1 patients, and from 45 Gy to
60 Gy for Type 2 patients. The rest of the bony structures
received an estimated dose of 5–45 Gy.
ICRT was interposed during the external radiation
course. Point A was defined on the X-ray as being 2 cm
superior to the vaginal sources and 2 cm lateral to the
cervical canal. ICRT was performed with a standard
prescribed dose to Point A of 4.2 Gy per fraction.
No chemotherapy was given to these patients.
Selected patients
Of the 381 patients included in NOCECA, 147 (39%) were
alive on January 1, 2005. These women received a mailed
invitation to take part in the study and a questionnaire
covering somatic impairments and QOL as well as
demography, comorbidity and life-style issues. Non-
responders received a written reminder after 3 weeks.
Details regarding diagnosis and treatment were retrieved
from the NOCECA clinical database.
Measures
Pain-definitions
Chronic pelvic pain was covered by seven self-made items
including pain in hips, groins, lower back, radiating pain,
pain in rest or activity, and pain influencing daily activities
(Table 2). The questions were not validated, however, our
clinical experience is that the items reflect important aspects
of pelvic pain to the patients. In this study, the Chronbach’s
alpha for the seven-item pain scale was α=.91. In addition,
there was a highly significant association between the seven
self-made items and the bodily pain scale of the MOS Short
Form-36 (SF-36). The items had the following possible
answers: “No/none”, “Monthly”, “Weekly”, “Daily”, and
“Constantly”. Each response was dichotomised as ‘no pain’
(no pain–monthly pain) or ‘pain’ (pain weekly–constantly),
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to 7 (maximum pain). Caseness of chronic pelvic pain was
defined as a sum score ≥2.
Pains in hips and lower back during a previous month
were scored as single items and dichotomised (pain orno pain
previous month). Daily pain was defined as pain in hips and
lower back 30 or 31 days during the previous month. The
items on pain in hips and lower back are similar to the
corresponding HUNT-2 questions. Therefore, we were able to
use the items in both questionnaires and compare the answers
from the patients with a healthy control group.
Bladder and intestinal problems
We used the Late Effects Normal Tissues-Subjective,
Objective, Management, Analytic (LENT-SOMA) subjec-
tive scale for bladder and intestinal symptoms [20]. The
LENT-SOMA is a self-rating instrument for measuring late
somatic impairment/problems after radiotherapy. The
LENT-SOMA scales have recently been incorporated into
the National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE). Severe bladder and
intestinal problems were operationalised according to
Vistad et al. [6], and here defined as severe self-reported
problems in at least one of these organs. Briefly explained,
the patients were classified as having severe problems when
they scored as having problems daily or constantly in five
of six intestinal items (e.g. Do you have any difficulty in
controlling your bowels) or five of five bladder items (e.g.
Do you suffer with incontinence of urine) [6]. Chronbach’s
alpha for the bladder scale was α=0,70 and for the
intestinal scale, α=0,82.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS)
[21] consists of 14 items, 7 from the depression subscale
(HADS-D) and 7 from the anxiety subscale (HADS-A).
Cases of clinically significant anxiety disorder or depres-
sion are defined with a score of ≥8o nH A D S - Ao r
HADS-D [22]. The HADS has shown excellent reliability
coefficients and psychometric properties in numerous
studies. For the CCSs in this study, Chronbach’sa l p h a s
were α=0,89 (HADS-A) and α=0,85 (HADS-D).
Physical and mental QOL
The SF-36 was used to assess QOL. The SF-36 [23]i sa
generic QOL questionnaire that consists of 36 items across
eight dimensions covering physical and mental QOL. Each
scale is scored from 0 to 100, with higher values indicating
more favourable QOL status. The dimensions can be
summarized as the Physical and Mental Component Sum-
mary Scales (PCS and MCS). The scales are calibrated so
that the value of 50 refers to the mean of Norwegian normal
population.
Other variables
Patients and controls were asked about mental problems
resulting in reduced daily activities of >1 year duration
(long-term mental complains), about daily smoking (yes/
no), and if they have a partner (yes/no). Further, they
were asked about daily use of any drugs (yes/no), and of
analgesics (yes/no). Three variables regarding the use of
hypnotics, anxiolytics, or antidepressants were combined
in the variable named psychotropics and rated as ‘yes’ if
at least one of these drugs were used daily. Educational
level was encoded based on the highest completed level
of basic education as three categories: compulsory school
(<9 years), high school (10–12 years), and college/
university level (≥13 years). Activities of daily living
were defined as personal care activities necessary for
everyday living.
NORMs
In the Health Study of Nord-Trøndelag County in 1995–97
(HUNT-2) [24] 35.280 women aged ≥20 years participated
(compliance rate 76%) and filled in a questionnaire
containing physical health among many other topics. Of
these women, 33.054 had not been treated for cancer
according to self-report, and represented the normative
control sample (NORMs).
In HUNT-2, invitations were sent by mail along with
questionnaire 1, which was to be returned when the women
came to the screening station. Questionnaire 1 contained
questions about demography and long-term mental com-
plaints. At the screening station all the participants received
questionnaire 2 which was to be filled in at home and
returned by mail. Items about pain in hips and lower back
in addition to use of drugs were included in questionnaire 2.
We have no normative controls for the cancer-specific
LENT SOMA-questionnaire.
Ethics
The study was approved by the institutional and regional
Committee for Ethics in Medical Research, Region South
and by the National Data Inspectorate of Norway. Every
patient gave written informed consent.
Data management and statistics
Dataweredescribedwithproportionsforcategorical variables
and with median and ranges for continuous variables. Crude
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square tests and unpaired t-test for continuous variables. Non-
parametric tests were applied when appropriate. The
Cochran–Armitage test was used to asses associations
between the seven pain items and the bodily pain scale in
SF-36.
Related variables were tested for multicollinearity
with Pearson’s correlations with a limit of r≥0.60.
Logistic regression analyses were performed with rele-
vant demographic, clinical and health variables as
independent variables and caseness of chronic pelvic pain
as the dependent variable. The associations were quanti-
fied as odds ratios (ORs) with 95% confidence intervals
(95% CI). We had a large sample from the general
population (the NORMS) at our disposal so we were able
to adjust for age in the logistic model instead of using
matching on age which could possibly lead to bias and
loss of efficiency. P-values <0.05 were considered
statistically significant and two-tailed tests were applied.
Data were analysed using the Statistical Package for
Social Sciences (SPSS version 14.0).
Results
Response rate and sample characteristics
Of the 147 eligible CCSs, 7 actively declined (5%) and 49
(33%) did not respond to the invitation. After one reminder,
a total of 91 CCSs returned completed questionnaires and
provided signed informed consent (response rate 62%). The
median age of responders was 62 years (range 37–92)
(Table 1).
Characteristics of CCSs versus NORMs
The NORMS were significantly younger than CCSs and we
thus adjusted for age. We found no statistically significant
differences between CCSs and NORMs concerning partner
status and educational level (Table 2). In a multivariate
logistic regression analysis, the age-adjusted risk of having
lower back pain was significantly higher for CCSs than
among the NORMs (OR 3.20, 95% CI: 2.09–4.91, p<.001),
while the risk of having hip pain was two and a half times
higher for CCSs compared to the NORMs (OR 2.60, CI
1.68–4.03, p<.001). Daily use of analgesics and hypnotics
was also significantly higher in CCSs compared to NORMs
(data not shown).
Demographical, physical and mental differences between
CCSs with and without pelvic pain
The CCSs’ self-rating of chronic pelvic pain is listed in
Table 3. Caseness of chronic pelvic pain was defined in 35
(38%) CCSs. Thirty percent (25/85) of the survivors
suffered from lower back pain daily or constantly, and
34% (26/76) complained of pain during activity daily or
constantly. Pain in groins was less often reported. Further-
more, activities of daily living were restricted due to pain in
almost one third of the CCSs (Table 3).
Comparisons of CCSs with or without chronic pelvic
pain revealed no significant differences in either socio-
demographic variables (age, partner-status, educational
level, employment status) or treatment related variables
(time since diagnosis, FIGO stage, treatment modality).
Use of analgesics was significantly higher among
patients with chronic pelvic pain (p=.001), while use of
medication in general did not differ between the two
groups.
Sixty percent of CCSs with chronic pelvic pain
complained of severe intestinal problems (especially
defecation-urgency and loose or watery stool) and 43%
reported severe bladder problems (especially stress incon-
tinence and urinary urgency). The corresponding propor-
tions among CCSs without such pain were 36% and 7% (6/
56), respectively (Table 4).
The mean levels of anxiety and depression and the
prevalence of HADS-defined anxiety and depression case-
ness were all significantly higher in CCSs with chronic
pelvic pain compared to those without. Among CCSs with
chronic pelvic pain 8/35 were considered clinically de-
pressed and 14/35 (40%) clinically anxious. The
corresponding numbers in those without pain were 3/56
and 9/56 (p<.001 for both). The patients were asked about
long-term mental complains, and there was no significant
difference between the two groups on this item. Concerning
QOL, significant differences were observed between CCSs
Table 1 Patient characteristics of 91 responders
Median age 62 (37–92)
Median follow-up (months) 100 (66–131)
FIGO Stage/substage, (N%)
Ib2 13 (14%)
IIb 65 (72%)
IIIa/IIIb 12 (13%)
IVa 1 (1%)
Histology
Squamous carcinoma 80 (88%)
Adenocarcinoma 8 (9%)
Adenosquamous carcinoma 3 (3%)
Treatment modalities
Type 1 (EBRT Dose 50/45 Gy + ICRT) 75 (82%)
Type 2 (EBRT Dose 45/60 Gy + ICRT) 9 (10%)
Extended radiation field 7 (8%)
J Cancer Surviv (2011) 5:208–216 211with and without chronic pelvic pain on all SF-36
dimensions (Fig. 1).
Associations between CCS with chronic pelvic pain
and various relevant variables
Unadjusted regression analyses of CCSs revealed signifi-
cant associations between caseness of chronic pelvic pain
and use of analgesics, intestinal and bladder morbidity, and
depression. In the multivariable logistic regression analysis
the use of analgesics and intestinal and bladder morbidity
remained significantly associated with chronic pelvic pain
in CCSs. (Table 5).
Discussion
To our knowledge this is the first study of a homogeneous
group of CCSs that focuses on self-reported chronic pelvic
pain and its associations after radiotherapy. We found that
the prevalence of daily lower back pain and hip pain were
significantly higher among the CCSs than in the general
female population. Using the seven-item case-finding
instrument, 38% (35/91) of the CCSs were defined as
patients with chronic pelvic pain. There was no statistically
significant association between either the presence of pelvic
pain and radiation treatment given, or duration of follow-up.
When present, chronic pelvic pain was strongly linked to
bladder and intestinal morbidity in both univariate and
multivariable regression analyses. Barker et al. [25]r e p o r t e d
on self-rated bladder and intestinal problems, as well as pain,
in a study involving 225 women 36 months after radiother-
apy. They found an increase in intestinal and bladder
problems after 36 months, but the scores on pelvic pain
were at the same level as pre-treatment. However, late-effects
after radiation are often progressive and may continue to
develop after 3–5y e a r s[ 26].
The prevalence of pelvic pain in CCSs varies greatly in
the literature. There are several possible explanations.
Firstly, the results are difficult to compare because of
various methods used to assess and analyze pain in different
studies. In many studies of CCSs, pain is assessed as a
single item in a QOL questionnaire without reference to its
location and with varying timeframes (e.g. daily pain, pain
during last week or last month). Furthermore, heteroge-
neous patient samples are studied regarding stage, sample
sizes, and treatment modalities. Li et al. [18] reported a
prevalence of lower back pain of 47% in CCSs. However,
their sample size was small (N=28) in ovaries removed
group), information on radiotherapy was scarce, and they
Variables CCSs (N=91) HUNT-2 NORMs (N=33,054) p-value
N (%) N (%)
Median age (range) 62 (37–92) 48 (19–98) <0.001
Smoking daily
a 34 (48) 9517 (31) 0.002
Has a partner
a 17 (50) 28 (53) 0.80
Educational level
a 0.87
<9 years 34 (38) 12428 (40)
10–12 years 38 (43) 12439 (40)
>13 years 17 (19) 6306 (20)
Lower back pain the previous month
a 47 (55) 9069 (27) <0.001
Daily lower back pain
a 25 (30) 1817 (6) <0.001
Hip pain the previous month
a 37 (45) 7202 (22) <0.001
Daily hip pain
a 18 (22) 1554 (5) <0.001
Table 2 Distribution of demo-
graphic and pain-related fac-
tors in CCSs and HUNT-2
NORMs
aAge-adjusted
None Monthly Weekly Daily Constantly
Proportions of positive ratings (%)
Lower back pain 38/85 (44) 12/85 (14) 10/85 (12) 21/85 (25) 4/85 (5)
Hip pain 45/82 (55) 8/82 (10) 11/82 (13) 15/82 (18) 3/82 (4)
Pain in groins 62/81 (77) 4/81 (5) 7/81 (9) 6/81 (7) 2/81 (2)
Radiating pain 54/86 (63) 4/86 (5) 8/86 (9) 17/86 (20) 3/86 (3)
Pain in activity 31/76 (41) 11/76 (14) 8/76 (11) 22/76 (29) 4/76 (5)
Pain in rest 48/77 (62) 4/77 (5) 8/77 (11) 11/77 (14) 6/77 (8)
ADL
a restricted 52/78 (68) 2/78 (3) 1/78 (1) 16/78 (20) 6/78 (8)
Table 3 Cervical cancer survi-
vors’ self-rating of pain in
pelvic region
aActivity of daily living
212 J Cancer Surviv (2011) 5:208–216asked about pain during the previous 4 weeks without
further specification.
Our results were more in line with findings of Bye et al.
[17] and Korfage et al.[27] in samples of CCSs. They
reported a prevalence of 19–22% [17, 27] of lower back
pain and 18% of hip pain [17] after radiotherapy. However,
their sample sizes were small, and the study groups were
heterogeneous with respect to treatment modalities (radio-
therapy only or in combination with surgery), stages and/or
diagnosis. Furthermore, one of the studies asked about pain
during the previous week [27], while no exact timeframe is
reported in the other study [17].
In some studies the prevalence of back pain is lower
than, or similar to the control group [16–19]. This was
not the case in our study, where the risks of having daily
lower back pain and hip pain were 3.2 and 2.6 times
higher in the CCS group than among the NORMs in the
age-adjusted analyses. The reason might be that we
analyzed daily pain, in contrary to many studies that
enquire about any pain during the previous month. As an
occurrence of any recent pain (last 4 weeks) is quite
common in the general population [28], our results
indicate that more specific reporting might be necessary
in order to reveal differences between a patient group and
the general population. In a Norwegian population study
(N=1,912), the prevalence of chronic lower back pain
among participating women was 14%, with no further
information regarding frequency of the pain reported [29].
The response rate was low (49%) compared to the
response rate in our control group (76%). In our study,
27% of the NORMs reported lower back pain during the
previous month; however, only 6% of NORMs had pain
on a daily basis. Hence, pain must be specified within a
timeframe in order to make comparisons possible.
Several studies of gynaecological cancer patients and
breast cancer patients reporting on pain indicate that
radiotherapy is more associated with long-term sequelae
of pain than surgery and chemotherapy [3, 4, 30–33]. The
bony structures of the pelvis lie in close proximity to the
uterine cervix. Therefore, these structures, as well as the
vagina, the bladder and the intestines will be affected by
irradiation of varying intensity. The patients in this study
were treated by conformal radiotherapy, and adjacent
tissue received higher doses of radiation than today, since
we now use a technique called intensity-modulation
radiation therapy (IMRT) [34, 35]. With the IMRT
approach, higher and more effective radiation doses can
safely be delivered to tumors with fewer side effects
compared with conventional radiotherapy techniques.
However, even though the radiation regimen has changed
since the women of this study were treated, several audits
and clinical studies suggest that the success of combining
radiotherapy with chemotherapy comes at a price in terms
of late morbidity. The effect of irradiation on bone tissue
is not completely understood; however, damage occurs at
the bone matrix and at the cellular as well as the vascular
level [3, 4, 36, 37]. This may lead to atrophy and further to
reduction of the functional components of the bony
structure, making it more susceptible to insufficiency
fractures at weight-bearing areas. In 1996, Blomlie et al.
[2] studied prospectively with Magnetic Resonance Imag-
ing (MRI) cervical cancer patients treated with radiother-
apy at the Norwegian Radium Hospital. Sixteen of 18
patients showed findings of insufficiency fractures within
12 months, whereof 21% of the lesions healed during the
observation period of 30 months. Recent studies have
reported the cumulative 5-year incidence of insufficiency
fractures diagnosed by MRI, to be 8.2–19.7% after pelvic
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Fig. 1 SF-36 dimensions in CCSs. All p-values <0.001 between the
CCSs with and without chronic pelvic pain. PF physical functioning,
RF role function, BP bodily pain, GH general health, VI vitality, SF
social functioning, RE role emotional, MH mental health
Pain (N=35) No pain (N=56) P-value Total sample (N=91)
Severe intestinal problems 21 (60) 20 (36) 0.023 41 (45)
Severe bladder problems 15 (43) 6
a <0.001 21 (23)
Caseness of depression 8
a 3
a 0.017 11 (13)
Caseness of anxiety 14 (40) 9
a 0.011 23 (25)
Long-term mental complains 7
a 4
a 0.076 11 (12)
Table 4 Physical and mental
symptoms in cervical cancer
survivors with and without
chronic pelvic-pain
aIf numbers are smaller than 10,
percentages are not given
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Though pain related to insufficiency fractures may be
severe in some patients, the symptoms are usually mild,
even asymptomatic [4, 36], and they cannot explain the
patient-reported prevalence of back pain extracted from
QOL studies of CCSs. Furthermore, if treated properly
(analgesics and rest), symptoms and MRI findings usually
disappear within 6–12 months after diagnosis [38]. We did
not examine our patients with radiographic examinations,
hence we do not know if any of these women suffered
from pelvic insufficiency fractures.
Chronic pelvic pain was associated with both intestinal
and bladder problems in the analyses. Individual variations
in the patients’ response to, and complications after
treatment have traditionally been explained as resulting
from either disease-related variables (stage of disease),
clinical health status (performance status, comorbid con-
ditions), or socio-demographic characteristics [39]. How-
ever, within the last decade there has been an increasing
interest in studies indicating that normal tissue radio-
sensitivity and cancer related symptoms can be predicted
from individual genetic profiles [40, 41]. Despite a small
number of survivors, our results indicate that approximately
one third experience long-term side-effects, involving
intestinal and bladder problems, as well as pelvic pain.
Maybe these patients were more susceptible to radiotherapy
than the other two thirds of the survivors?
CCSs with pelvic pain scored significantly lower on all
dimensions of the SF-36 compared to those without pelvic
pain. However, one has to be aware that bodily pain is one
of the items in the PCS scale and thus influence the overall
score on SF-36. The findings are consistent with reports
from studies of breast and gynaecologic cancer survivors
showing that pain may have a significant impact on QOL
and day-to-day well-being of the survivors [42].
Strengths and limitations
A major strength of this study is that we considered a group
of CCSs that was homogeneous with respect to treatment
modality (radiotherapy) and time since diagnosis (≥5 years).
We used standardized instruments covering QOL and
anxiety and depression. In addition, we were able to adjust
for age and compare our CCSs with a normative sample
using logistic regression models. Furthermore, clinical data
on the non-participating CCSs were available indicating
that this group did not differ significantly from the study
group, thus limiting a possible selection bias.
A weakness of our study is the use of ad hoc items to
assess for chronic pelvic pain. We were unable to
identify case finding screening tools, and these items
were based on clinical experience and syndrome defi-
nitions. While further work is needed to validate these
findings in other populations, the questions used in this
study had promising psychometric correlations, and can
help guide clinical assessments and serve as a basis for
future studies. We also had a small sample size with a
considerable risk of type II statistical error implying that
some of our results could be statistically significant with
larger sample size and thus increased statistical power.
Since CCSs were assessed cross-sectionally, we have no
information concerning pre-morbid physical and mental
status that could have influenced outcome variables like
pain, anxiety, depression, and bladder and intestinal
complaints. Another weakness is that we did not
examine the patients with biopsies or radiographic
examinations in order to detect pathological differences
due to radiation sequelae between the groups with and
without pelvic pain. The preferable method would have
been to physically examine all the women at the Radium
Hospital. However, it would involve travelling for the
majority of these women who were elderly, and only a
few lived in Oslo, so this alternative was not feasible.
Conclusion
We have shown that the CCS have a higher prevalence of
pain in lower back and hips than women from the general
population, which might be due to late effects of radiation.
Variables Univariate Multivariate
OR 95% CI p-value OR 95% CI p-value
Employed (ref) 1.00
Unemployed /pensioned 0.52 0.20–1.38 0.16
Long-term mental complains 0.32 0.85–11.83 0.87
Psychotropics 2.18 0.33–14.36 0.42
Analgesics 4.93 1.86–13.06 0.001 3.77 1.26–11.27 0.02
Bladder/intestinal problems 3.59 1.45–8.88 0.006 3.39 1.18–8.96 0.01
Depression
a 4.94 1.21–20.17 0.026 2.43 0.48–12.35 0.77
Table 5 Univariate and multi-
variate logistic regression
analyses of independent
variables and caseness of
chronic pelvic pain in CCSs as
dependent variable (without
pain = reference)
aAnxiety was not included in the
analyses due to multicolinearity
214 J Cancer Surviv (2011) 5:208–216Pain after pelvic radiotherapy may negatively affect rehabil-
itation, increase suffering, and negatively influence QOL.
Therefore, future research should focus on methods for
preventing morbidity of the pelvic organs without compro-
mising tumour control. Furthermore, a thorough evaluation of
pelvic pain is important; both to establish the appropriate
diagnosis and toruleout cancer recurrence in the follow-up of
CCSs. Management of chronic pain in CCSs should be
optimized by a multidisciplinary approach involving the use
ofanalgesics, physicaltherapy, interventionalprocedures, and
psychosocialinterventions. In addition, assomepatientsseem
to be more susceptible to radiation therapy in terms of
developing long-term mental and physical morbidity, pre-
dicting an individual’s risk of radiation-induced normal tissue
complications prior to cancer therapy should be a priority in
clinical radiobiology studies.
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